Lv1
34 积分 2021-02-13 加入
Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
2天前
已完结
Defining immune reset: achieving sustained remission in autoimmune diseases
7天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
18天前
已完结
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB
19天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
19天前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
20天前
已完结
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
20天前
已完结
A clinical certification pathway for generalist medical AI systems
1个月前
已完结
Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024
1个月前
已完结
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade
2个月前
已完结
皖公网安备34019202002308
